



**ISHLT ACADEMY CORE COMPETENCIES COURSE ON
MECHANICAL CIRCULATORY SUPPORT**

Tuesday, April 26, 2016

8:00 AM – 5:30 PM

Marriott Wardman Park Hotel, Washington DC, USA

Thurgood Marshall Ballroom East

**ISHLT ACADEMY CORE COMPETENCIES COURSE ON
MECHANICAL CIRCULATORY SUPPORT**

**Tuesday, April 26, 2016
8:00 AM – 5:30 PM**

Scientific Program Committee

Chair: Jennifer Cowger, MD, MS, St. Vincent Heart Center of Indiana, Indianapolis, IN, USA

Co-Chair: Daniel Zimpfer, MD, Medical University of Vienna, Vienna, Austria

Co-Chair: Jennifer Beckman, MSN-FNP, RN, CHFNP, University of Washington, Seattle, WA, USA

Educational Goals

The educational goals of this activity are to provide a concise review of clinical knowledge and essential professional skills to facilitate best practice of surgical and medical aspects involved in the care of patients during assessment as candidates and as recipients of mechanical circulatory support.

Target Audience

While all members are invited to enroll, this course is primarily designed to be of benefit for clinicians and allied professionals who are in the early stages of their careers or who are in training and/or are part of a new program or desire an update on the current state of the field. The information presented covers core competencies and is intended to provide a strong foundation of the overarching principles of mechanical support, rather than as a detailed update for those who are already proficient experts in the field.

Accreditation Statement

The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

ISHLT designates this live activity for a maximum of 8.00 AMA PRA Category 1 Credits.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC Credit

Amedco is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This course is co-provided by Amedco and the International Society for Heart and Lung Transplantation (ISHLT). Maximum of 8.00 contact hours.

Disclosure

Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker's presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. Please refer to the Participant Notification document for a list of all disclosures. Additionally, all speakers have been asked to verbally disclose at the start of their presentation if a product they are discussing is not labeled for the use under discussion or is still investigational.

Learning Objectives

At the conclusion of this meeting, participants will have improved competence and professional performance in their ability to:

1. Understand how to risk stratify patient with advanced heart failure in order to assess MCS surgical risk and optimally time mechanical circulatory support (MCS) implantation.
2. Recognize the medical and social factors which impact patient outcomes during short- and long-term MCS.
3. Recognize the various types of MCS support available for patients with advanced single or biventricular heart failure and the technological differences that may impact pump selection and patient/device management.
4. Optimize MCS implantation techniques and patient/pump management during the index admission intensive care unit and inpatient general care periods.
5. Manage patients and the MCS during outpatient long-term support with an understanding of interventions that can reduce patient- and device-related adverse events during MCS.
6. Diagnose and manage common clinical dilemmas and adverse encountered after MCS.

SCIENTIFIC PROGRAM SCHEDULE

7:15 AM – 8:00 AM

REGISTRATION AND MORNING COFFEE

8:00 AM - 9:15 AM

SESSION 1: REVIEW OF THE CURRENT STATE OF MCS

Co-Chairs: Stephan Schueler, MD, PhD, FRCS & Christian Schlensak, MD

8:00 AM *Welcome and Overview*

Jennifer Cowger, MD, MS, St. Vincent Heart Center of Indiana, Indianapolis, IN, USA

8:15 AM *MCS Tech 101 Pumps and Load*

Scott Silvestry, MD, Florida Hospital Transplant Institute, Orlando, FL, USA

Review of current technologies available, pump behaviors with different loading conditions, and the TAH.

8:30 AM *BTT and DT Outcomes & Adverse Events*

Andreas O. Zuckermann, MD, PhD, University of Vienna, Vienna, Austria

Review state of outcomes and adverse events with current technologies

8:45 AM *Short-term Mechanical Support*

Jonathan Haft, MD, University of Michigan, Ann Arbor, MI, USA

Overview of percutaneous technologies, biventricular support considerations, and ECMO.

9:00 AM Q&A

9:15 AM – 10:30 AM

SESSION 2: PATIENT SELECTION

Chair: Scott Silvestry, MD

9:15 AM *When Should Patients be Referred: Warning Signs*

Douglas Horstmanshof, MD, Integris Baptist Medical Center, Oklahoma City, OK, USA

Risk factors which presage patient decline (renal function, intolerance of medications, hospitalizations, etc, helping to risk stratify patients based on HF severity and MCS operative risk.

9:30 AM *Assessing and Optimizing RV Function Preoperatively*

Anna Meyer, MD, University of Leipzig, Leipzig, Germany

Impact of RV failure, pre-operative assessment and management of the RV including imaging and risk prediction.

9:45 AM *Quality of Life After VAD and the Impact of Frailty and Social Behaviors on VAD Success*

Susan Joseph, MD, Washington University School of Medicine, St. Louis, MO, USA

Other factors that can have a significant impact on success after VAD and some screening tools available for risk assessment.

10:00 AM *Other Medical Co-Morbidities that May Impact VAD Success*

Douglas Horstmanshof, MD, Integris Baptist Medical Center, Oklahoma City, OK, USA

Impact of peripheral vascular disease, end-stage renal failure, and other chronic medical illnesses on short and long term VAD success.

10:15 AM Q&A

10:30 AM – 10:45 AM

COFFEE BREAK

10:45 AM – NOON

SESSION 3: SURGICAL CONSIDERATIONS

Chair: Vivek Rao, MD, PhD

10:45 AM *LVAD Implantation: Key Surgical Aspects*

Nader Moazami, MD, Cleveland Clinic, Cleveland, OH, USA

Overview of the most crucial surgical considerations: inflow cannula/pump placement, driveline, etc.

11:05 AM *Concomitant Interventions: How Much is Too Much?*

Daniel Zimpfer, MD, Medical University of Vienna, Vienna, Austria

Concomitant operative procedures: TV, Aortic valve, prior Dor, congenitals

11:25 AM *Tailoring Pumps to Patients*

Christian Schlensak, MD, University Tuebingen, Tuebingen, Germany

Case based discussion of considerations for pump-patient matching

11:45 AM Q&A

NOON – 1:00 PM

LUNCH BREAK (a box lunch is included in the registration fee)

1:00 PM – 2:15 PM

SESSION 4: POSTOPERATIVE CARE

Chair: Andreas Zuckermann, MD

1:00 PM *Managing the RV Post LVAD*

Christopher Salerno, MD, St. Vincent Heart Center, Indianapolis, IN, USA

Considerations for impact of LVAD pump speed on RV function and use of inotropes and pulmonary vasodilators

1:20 PM *Anticoagulation in VAD Recipients*

Vivek Rao, MD, PhD, Toronto General Hospital, Toronto, Canada

Current MCS recommendation on when to start anticoagulation, antiplatelet therapy regimens, as well as data on platelet function testing and heparin level monitoring.

1:40 PM *Pump Speed Optimization: The Role of Imaging and Hemodynamics*

Nir Uriel, MD, University of Chicago, Chicago, IL, USA

Overview of how to meld imaging and hemodynamics to optimize pump settings

2:00 PM Q&A

2:15-3:15 PM

SESSION 5: TRANSITION TO HOME

Chair: Nir Uriel, MD

2:15 PM *VAD Education: Tips and Tools for Patient Success*

Thomas Schloeglhofer, BSc, Medical University of Vienna, Vienna, Austria

Approaches to education of the patient and caregiver prior to discharge, and strategies for educating the local medical community

2:30 PM *Starting New: How to Start and Succeed in MCS*

Michael Dickinson, MD, Spectrum Health, Grand Rapids, MI

Challenges to starting a VAD program and key elements of success.

2:45 PM *The Outpatient Clinic: Laboratory, Blood pressure, and Echo Monitoring*

Jennifer Beckman, MSN-FNP, RN, CHFNP, University of Washington, Seattle, WA, USA

Lab, blood pressure and echo monitoring of VAD patients in the outpatient setting.

3:00 PM Q&A

3:15 PM - 3:30 PM

COFFEE BREAK

3:30 PM - 5:20 PM

SESSION 6: LONG TERM MANAGEMENT OF PATIENTS AND COMPLICATIONS

Chair: Nadir Moazami, MD, Cleveland Clinic, Cleveland, OH, USA

3:30 PM LVAD Infections: Prevention, Diagnosis, and Management

Margaret Hannan, MD, Mater Misericordiae University Hospital, Dublin, Ireland

VAD infections, radiology studies important for diagnosis, and therapeutic recommendations

3:50 PM Stroke: Risk factors for Hemorrhagic and Embolic CNS Complications and Management Strategies

Samer Najjar MD, MedStar Heart institute, Washington, DC, USA

Discuss diagnosis, risk factors, and management strategies for CNS events in MCS patients.

4:10 PM Pump Thrombosis

Simon Maltais, MD, PhD, Mayo Clinic, Rochester, MN, USA

Frequency, diagnosis, and management strategies for suspected pump thrombosis.

4:30 PM Aortic Insufficiency in LVAD Recipients: Incidence, Screening, and Management

Jennifer Cowger, MD, MS, St Vincent Heart Center of Indiana, Indianapolis, IN, USA

Cumulative incidence, clinical consequences, and management of AI after LVAD.

4:50 PM Gastrointestinal Bleeding in CF LVAD Patients

Keyur Shah, MD, Virginia Commonwealth University, Richmond, VA, USA

Frequency, diagnosis and management of GI bleeding after LVAD therapy, including new data on octreotide

5:10 PM Q&A

5:20 PM SUMMARY

5:30 PM ADJORN